Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group-Reference-Cited by-同舟云学术

Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group

Published:2009-09-08 Issue:7 Volume:101 Page:1039-1043
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Garcia-Alfonso P,Muñoz-Martin A,Mendez-Ureña M,Quiben-Pereira R,Gonzalez-Flores E,Perez-Manga G

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605261.pdf

Reference29 articles.

1. Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di PM (2004) New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev 30: 555–562

2. Bajetta E, Di BM, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R (2004) Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100: 279–287

3. Benson III AB, Goldberg RM (2003) Optimal use of the combination of irinotecan and 5-fluorouracil. Semin Oncol 30: 68–77

4. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16: 282–288

5. Borner MM, Schoffski P, de WR, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der BK, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT vs intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38: 349–358

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effective combination therapies with irinotecan for colorectal cancer;Frontiers in Pharmacology;2024-02-05

2. Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review;Cancers;2022-05-17

3. Oral drugs in the treatment of metastatic colorectal cancer;Therapeutic Advances in Medical Oncology;2021-01

4. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future;Pharmacology & Therapeutics;2020-02

5. Colorectal Cancer;Abeloff's Clinical Oncology;2020